Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $43
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $43
Wells Fargo analyst Derek Archila maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and adjusts the target price from $47 to $43.According to TipRanks data, the analyst has a success
Evaluating Market Dynamics and Physician Preferences: Hold Rating on Apellis Pharmaceuticals Amid Syfovre and Izervay Competition
Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $92
Baird analyst Colleen M. Kusy maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and adjusts the target price from $96 to $92.According to TipRanks data, the analyst has a success rate
Express News | Apellis Pharmaceuticals Inc : Baird Cuts Target Price to $92 From $96
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $61
BofA Securities analyst Tazeen Ahmad maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and maintains the target price at $61.According to TipRanks data, the analyst has a success rate
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $39 to $85
On Sep 21, major Wall Street analysts update their ratings for $Apellis Pharmaceuticals(APLS.US)$, with price targets ranging from $39 to $85.BofA Securities analyst Tazeen Ahmad maintains with a
Apellis Pharmaceuticals Is Maintained at Neutral by Mizuho
Apellis European Rejection for Vision Treatment Dents Revenue Growth, Stock Performance, Wedbush Says
Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
What's Going With Apellis Pharmaceuticals Stock Friday?
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $35 From $41, Maintains Neutral Rating; Shares Fall
Buy Rating on Apellis Pharmaceuticals Anchored in Syfovre's Market Share Potential Despite EU Setback
Sector Update: Health Care Stocks Rise Premarket Friday
Express News | Apellis Pharmaceuticals Inc : Piper Sandler Cuts Target Price to $40 From $46
Sector Update: Health Care
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $39
Mizuho Securities analyst Graig Suvannavejh maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and sets the target price at $39.According to TipRanks data, the analyst has a success
Express News | Apellis Pharmaceuticals Shares Down 5.8% Premarket After EU Panel Confirms Negative Opinion for Eye Disease Drug
Apellis: CHMP Once Again Recommends Against Syfovre